JB Chemicals and Pharmaceuticals Limited (JBCPL) Q2 FY21 revenue is down 3% to reach Rs. 443.6 crore and PAT (Profit After Tax) is down 21% to reach Rs. 73.9 crore. 

 

Commenting on business outlook, Nikhil Chopra, CEO, JBCPL said, “I am delighted to be at the helm of JBCPL, a company with a strong business model and multi-pronged drivers of long-term growth. With management control transitioning to KKR and the new management team coming on board, the company is uniquely positioned to capitalize on opportunities in formulations, contract manufacturing and API’s. We have a rich legacy to build on – supported with best in class manufacturing facilities, unique lozenges platform and strong brands." 

 

"Our future path to value creation will focus on: Portfolio ramp up and building bigger brands in domestic formulations; Strengthening of R&D to support filings & dossier registrations in regulated and semi-regulated markets; Expansion of lozenges platform to support our CMO business; Deeper focus on Business Development and Strategic Partnerships along with synergistic acquisitions," commented Chopra. 

 

"As we embark on this new journey, Technology Enablement and People Empowerment will be reflected in every act we do. So far, we have seen strong operating performance across business units in the first half of FY21. As we move into the second half of the financial year, we look forward to formulating and kickstarting several initiatives that we believe will enhance stakeholder value in line with potential,” added Chopra. 

 

Exports order book remains healthy (Sep 20 order book growth of 39% over Sep 19) – however Rs. 57 crore of planned Q2 dispatches have been deferred to October due to constrained availability of ships/containers. Domestic Formulations business continues to outpace IPM growth rates, driven by sales performance in chronic therapies.